The FDA has approved marnetegragene autotemcel (Kresladi) as the first gene therapy to treat children with severe leukocyte adhesion deficiency type I (LAD-I). LAD-I is a rare inherited immunodeficiency. The approval was granted in an accelerated procedure. Kresladi is intended for patients aged one month and older. This is the first gene therapy approved for this particular disorder.